“At AMR we strive to be the best. And to be recognized by our clients and peers in this industry as such is truly the highest honor.”
Spring Hill, TN (PRWEB) April 15, 2015
Presented at the World Vaccine Congress 2015 in Washington, D.C., the vaccine industry came to a consensus that The Alliance for Multispecialty Research had outperformed the competition in the trial network field. The Vaccine Industry Excellence (ViE) Award for “Best Clinical Site/Network” recognizes the efforts, accomplishments, and positive contributions to the vaccine industry by a clinical research site/network.
“At AMR, we strive to be the best. And to be recognized by our clients and peers in this industry as such is truly the highest honor,” said Brenda Atchison, Executive Director of the Alliance for Multispecialty Research. “This recognition can be attributed to our research professionals and partner organizations across the country. Additionally, a special thanks is in order for the 40,000+ volunteers that have participated in a vaccine study across our AMR sites. It is their volunteering that has enabled us to provide this level of service to our Sponsors and CROs.”
The Best Clinical Trial Site or Network award winner was chosen through a combination of vaccine industry peer input, online voting, and a panel of industry judges. Criteria used by the judges included the following:
- Matching clinical development needs through a complete programmatic assessment.
- Support of multiple and diverse clinical phase and outcomes trials for vaccines.
- Methods of performance improvement or introduction of new services.
- Rapid enrollment across a vaccine ranges and outstanding study subject retention.
- Reaching of milestones and final / ongoing outcomes / trials.
“Our proficiency in conducting vaccine clinical trials of all phases across diverse populations in a breadth of indications ranging from A to Z (anthrax to zosters) is really what earned us this award,” said Atchison.
Over the course of its existence, AMR has collaborated with more than 30 vaccine sponsors across 36 different vaccine indications. Its broad range of vaccine experience includes indications such as C. difficile, ebola, candidiasis, smallpox, cholera, anthrax, plague, botulism, H1N1/H5N1, dengue, smoking cessation, and melanoma. Cumulatively, AMR's 14 principal research centers have carried 460 study slots on vaccines programs, some of which were bioterrorism-related and government sponsored initiatives, enrolling just over 33,000 study volunteers.
AMR is comprised of 17 independent multi-therapeutic clinical research Centers of Excellence in 17 metropolitan areas across the United States. AMR, LLC employs more than 400 research professionals and averages 25 years of existence per site. Continued investigative success is achieved through implementation of the alliance’s Core Team Process and a controlled competitive enrollment model. AMR, LLC is committed to providing Sponsors with the highest level of quality and accuracy. In reflection of this mission and award, the network plans to launch a new line of business committed solely to vaccine research, to be called Vaxsites, in Q2 of 2015.
To learn more about AMR, please visit http://www.AMRLLC.com. The Alliance for Multispecialty Research is an Investigative Site Network of Excellence. AMR is a privately held organization.
For more information, please contact:
Name: Brenda S. Atchison
Title: Executive Director